Novartis Reports Phase 3 ASC4FIRST Results for Scemblix in Frontline CML

Novartis today announced results from the Phase 3 ASC4FIRST trial evaluating asciminib (Scemblix) versus investigator-selected standard-of-care tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, or bosutinib) in patients with newly diagnosed chronic myeloid leukemia in chronic phase. The trial met its primary endpoint, demonstrating a statistically significant improvement in major molecular response rate at week 48 for asciminib. These results support asciminib as a potential new first-line treatment option for CML and led to FDA approval in this setting.